Coherus Biosciences (NASDAQ:CHRS) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Thursday.

A number of other equities analysts also recently issued reports on CHRS. Credit Suisse Group reissued an “outperform” rating and set a $17.00 target price (down from $24.00) on shares of Coherus Biosciences in a research note on Wednesday, September 27th. ValuEngine raised Coherus Biosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Maxim Group reissued a “buy” rating and set a $20.00 target price (down from $40.00) on shares of Coherus Biosciences in a research note on Friday, September 8th. Cowen reissued an “outperform” rating and set a $45.00 target price on shares of Coherus Biosciences in a research note on Friday, September 8th. Finally, Zacks Investment Research downgraded Coherus Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, September 12th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $30.00.

Coherus Biosciences (CHRS) opened at $9.45 on Thursday. Coherus Biosciences has a one year low of $8.05 and a one year high of $29.59. The company has a debt-to-equity ratio of 1.84, a quick ratio of 5.46 and a current ratio of 5.46.

Coherus Biosciences (NASDAQ:CHRS) last issued its earnings results on Monday, November 6th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.26). Coherus Biosciences had a negative return on equity of 582.31% and a negative net margin of 73.89%. equities research analysts predict that Coherus Biosciences will post -4.39 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC increased its stake in Coherus Biosciences by 32.7% in the 2nd quarter. SG Americas Securities LLC now owns 7,244 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 1,785 shares in the last quarter. Legal & General Group Plc increased its stake in Coherus Biosciences by 12.6% in the 2nd quarter. Legal & General Group Plc now owns 9,341 shares of the biotechnology company’s stock valued at $134,000 after purchasing an additional 1,046 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. increased its stake in Coherus Biosciences by 497.4% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,600 shares of the biotechnology company’s stock valued at $168,000 after purchasing an additional 10,491 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in Coherus Biosciences in the 2nd quarter valued at approximately $185,000. Finally, Voya Investment Management LLC increased its stake in Coherus Biosciences by 32.2% in the 2nd quarter. Voya Investment Management LLC now owns 17,607 shares of the biotechnology company’s stock valued at $253,000 after purchasing an additional 4,293 shares in the last quarter. 81.00% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “BidaskClub Upgrades Coherus Biosciences (CHRS) to “Hold”” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.watchlistnews.com/bidaskclub-upgrades-coherus-biosciences-chrs-to-hold/1775404.html.

Coherus Biosciences Company Profile

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Analyst Recommendations for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.